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INTRODUCTION
The National Institute for Clinical Excellence Guidelines for Eating Disorders (1) recommend that a specific form of cognitive-behavior therapy for bulimia nervosa (CBT-BN) (2) should be given to most adults. The statement was based on evidence from randomized controlled trials, which generally assess the efficacy of treatment under optimal conditions (highly selected patients, recruited via advertisements and treatment delivered by research clinicians with tightly controlled treatment procedures). Many patients presenting to outpatient services do not have full syndromal bulimia nervosa (BN) and instead present with subthreshold or partial syndromes (3)' very few studies (4 -7) of reasonable size (i.e., participants, and were moderated by two therapists. To ensure continuity, therapists running groups also saw patients for Phase 1 treatments so that each group participant had one of the two co-leaders as their therapist during the first four sessions. Both co-leaders played equal roles.
In contrast to the well-known CBT-BN program of Fairburn and colleagues (2) , the group treatment used here (19, 21) is briefer (8 versus 19 sessions) and emphasized women's development of interpersonal competencies.
Therapist Training and Supervision
Therapists were all drawn from health service personnel in the Eating Disorders Unit at the Maudsley Hospital and included psychologists, psychiatrists, nurses, or occupational therapists, all of whom were experienced in the treatment of eating disorders and the delivery of MET and CBT. To avoid therapist bias, all therapists delivered the three conditions. All received the following: MET training during a 2-day workshop; a training day on the use of the group program; and a 2-day workshop on the delivery of manual-guided CBT. Weekly supervision was mandatory for all therapists and was conducted on a one:one basis for individual treatment and with co-therapists for the group intervention. Supervision arrangements for the first 4 weeks of treatment were kept strictly separate and conducted by separate supervisors who were either experienced CBT (Padmal de Silva) or MET trainers (J.T., U.S.). Dr. Katzman provided supervision to all three experimental groups during the last 8 weeks of the trial, again with separate supervision for cases being treated in individual or group treatment. During the first 4 weeks, all treatment conditions (MET-I, MET-G, CBT-G) generated a "product" (thought records, motivational letters, etc). These were checked for quality in supervision. Moreover, precisely how materials were used in therapy and integrated into the treatment of different patients was reviewed in supervision on a regular basis. In Phase 2, all diaries and flip charts were collected weekly and reviewed by supervisors.
Assessment
All patients were assessed for suitability by an experienced clinician, using a standardized semi-structured interview format (22) (23) (24) . The English version of the interview was developed by eating disorder experts in the context of a European project (COST ACTION B6). Previous versions of the interview had been used in a large German multi-center, naturalistic study on outcome of eating disorders (project TREAT) (22) . The interview included variables from the LIFE (24) and the EDE (23) assessing eating disorder symptoms, use of drugs, and alcohol and antidepressant medication. A pre-treatment battery (22) included basic clinical features and demographics, along with well-validated, widely used questionnaires, such as the Symptom Checklist 90 (25) . The primary treatment outcomes were key behavioral symptoms (binge eating, self-induced vomiting, laxative/diuretics abuse) that were measured, using the short evaluation of eating disorders (26 -28) . This is a brief, valid, and reliable self-report measure assessing eating disorder symptoms over the last 4 weeks. There is excellent interrater reliability with values of > 0.70 between patient selfratings and those independently made by an "expert" (therapist or clinical researcher).
Patients and therapists rated these variables separately at pretreatment, 4 weeks (after Phase 1) and at 12 weeks (after Phase 2). Only patient ratings collected by research assistants blinded to their treatment allocation are available for the 1-year follow-up and the 2.5-year follow-up. All outcomes were assessed for the time period of the previous month.
An additional outcome variable, motivation to change and dropout, was assessed with the University of Rhode Island, Change Assessment Scale (29) . This questionnaire, completed by the patient, offers four scales-precontemplation, contemplation, action, and maintenanceas well as assigning patients to a particular stage on the basis of the scale with the highest score.
Definitions of Treatment Completion and Dropout
There is little agreement between studies on how to define treatment adherence and dropout. 
Analysis
Demographic information and baseline data were analyzed, using SPSS 8.0 (SPSS, Inc., Chicago, Illinois) for windows. Data were compared using t-tests, analysis of variance, or χ 2 .
Eating disorder symptomatology was analyzed, using the Stata program gllamm (30) . For this, analysis outcomes for eating disorder symptoms (bingeing, vomiting, laxative use) were examined separately to determine whether motivational pre-treatment might have a different effect on different symptoms (given that clinical experience suggests that patients' motivation to change differs between symptoms).
The patient and therapist ratings of the frequency of bingeing, vomiting, and use of laxatives were collapsed into three comparable and clinically relevant categories: 0 = abstinence; 1 = infrequent behaviors (i.e., < 2 times a week); and 2 = frequent behaviors (≥ 2 times a week).
Therapist and patient ratings of each type of behavior were analyzed separately. A proportional odds model for repeated measures was used to model the effect of treatment, time, and time by treatment on the odds of being rated in the higher categories (2 versus 1, 0 or 2, 1 versus 0). A random effect for subjects was included in the model to take account of correlations among the observations on the same subject. The effect of time was modeled by a linear trend in the log-odds. The significance of the interaction was tested, using a Wald test. If significant, the linear trend of time was compared between the groups with and without motivational enhancement therapy and between the group treatment and individual treatment groups. If the group by time interaction was not significant, the model was reestimated with the main effects of group and time only.
Our analyses were based on intention to treat, which meant that although each subject contributed different numbers of observations, we were able to make more efficient use of the data than the more common complete case analysis used for repeated-measures data. This approach also allowed us to analyze whether specific variables, such as dropout or stage of change, predicted outcome. The parameters were estimated by maximum likelihood, using adaptive quadrature. Maximum likelihood estimation provides consistent parameter estimates if the data are missing at random. Table 1 , analysis of variance revealed no significant differences between any of the three groups on baseline characteristics apart from a difference in age, which although statistically significant (p < .05) was not clinically meaningful (mean age, 29.3 years; MET-I, 31 .0 years; MET-G, 28.9 years; CBT-G, 27.8 years). For the groups combined, the average body mass index (kg/m 2 ) was 24.7 (7.5). Table 1 about here
RESULTS

Recruitment and Progression of Patients Through the Study
The three groups reported no difference at baseline on bingeing, vomiting, or laxative use.
These variables were rated, using a 5-point scale ("1 = not at all," "2 = up to 1× per week," "3 = 2 to 3× per week," "4 = 4× per week up to daily," "5 = > 1× day"). It is of note that considerable proportions of patients took antidepressant medication, (42.4% of the 172 patients for whom this information was available), used alcohol regularly (51.5% of the 165 patients for whom this information was available) or were taking illicit drugs (42.1% of the 155 patients for whom this information was available). The participants drank between 4 times a week to daily (10% drank more than once daily). This suggests high levels of comorbid substance abuse and depression, which did not differ between groups (Pearson's χ Treatment Uptake, Adherence, and Dropout There were no significant differences in treatment uptake, completion, and dropout between groups (Fig. 2) . Patient ratings of symptom abstinence beginning to end of treatment are illustrated in Table 2 . 
Patient Rating
There was no significant group by time interaction (p = .64). The reduction in the odds of bingeing over time was significant (p < .001; OR, 0.39; 95% CI, 0.31-0.49). The patient rating of bingeing over time tended to be lower if the patient was in a higher stage of change at the time of assessment (p = .02), i.e., more motivated. The SCL-90 and completion of Phase 1 had no significant effect on the patient ratings of bingeing.
Self-Induced Vomiting
Therapist Rating
Vomiting as rated by the therapist did not show a significant group by time interaction (p = .62). There was a significant main effect of time. At every assessment, the odds of vomiting decreased to 36% of its value at the previous assessment (p < . 
Patient Rating
The patient rating showed no significant group by time interaction ( Abstinence Rates Table 3 illustrates abstinence rates for bulimic behaviors over time as rated by the patients and therapists. Given the lack of differences between the three groups on the key behavioral variables, overall abstinence rates were calculated for patient and therapist. For binge eating, the overall abstinence rates on the therapist assessment were 12.5% at baseline and 46% at post treatment. Patient rating of bingeing abstinence was 2.5% at baseline, 29% at post treatment, 40% at 1-year follow-up, and 46% at 2.5-year follow-up.
For self-induced vomiting, the overall abstinence rate by therapists was 23% at baseline and 45% at post treatment. Patient rating of self-induced vomiting was 21% at baseline, 29% at post treatment, 54% at 1-year follow-up, and 46% at 2.5-year follow-up.
For abstinence from laxative/diuretic abuse, therapists rated 67% at baseline and 87% at post treatment. Patients reported abstinence rates of 59% at baseline, 75.3% at post-treatment, 80% at 1-year follow-up, and 85% at 2.5-year follow-up.
DISCUSSION
This is a large-scale, pragmatic catchment area-based investigation of treatment effectiveness for bulimic disorders (BN and EDNOS).
Main Findings
Patients in all three conditions improved significantly on key behavioral outcomes (frequency of bingeing, vomiting, and laxative abuse). The degree of improvement on these parameters is in keeping with those found in other studies (1, 31) . It is noteworthy that patients reported more binge eating than therapists-perhaps because the patients themselves do not distinguish between subjective and objective binges.
There were no differences between conditions on bingeing or vomiting (whether assessed by the patient or the therapist). While on the therapist rating of laxative abuse there was a significant group by time interaction, the patient rating of laxative use failed to confirm this.
As only a small proportion of patients used laxatives, overall there is less certainty about this finding.
There were no differences between groups in treatment up-take, completion, or dropout rates.
The dropout rates found here, although higher than those reported in efficacy studies, were comparable to those reported in the context of other sample, using individual or group CBT in routine clinical settings (11, 32) .
MET Versus CBT in the First Treatment Phase Our first hypothesis was that MET would improve treatment adherence and reduce dropout from treatment in patients with BN. This hypothesis was not supported. However, our findings do suggest that MET constitutes an acceptable alternative to CBT early in treatment, which is of both theoretical and practical importance. Theoretically, this is significant because MET involves different processes to CBT (33); the latter, for example, uses self-monitoring among other forms of actionorientated behavior change principles in the early stages of treatment. It has been found that the response to CBT in the first six sessions is a strong predictor of later outcome (34) . Those patients who find it difficult to comply with active strategies may respond better to MET. The majority of patients in this study were in the contemplation stage at baseline, and none were in precontemplation (35) . Motivational interviewing is a less useful intervention in people who are ready to change (36) . It is possible that the use of MET may be shown to be more effective in improving adherence and subsequent outcome in a less motivated group than the current sample who had sought clinical help.
Group Versus Individual Treatment
Our second hypothesis was that adding a brief individual component to group treatment can produce comparable results to solely individual treatment of the same duration. Patients in our study did equally well whether treated individually throughout or in an individual plus group setting in Phase 2. This finding counters past research, which suggests that group treatment produces higher dropout rates and may be less effective in reducing key behaviors, such as self-induced vomiting (37) .
It is possible that our paper was underpowered to find statistical significance in abstinence rates between the group and individual conditions. However, it is worth considering several It is also notable that the length of our group treatment was 8 weeks, which is shorter than other group interventions described in the literature. However, Wolchik et al. (21) reported clinically significant findings after 7 weeks, and other investigators have reported that most change happens in the early phase of care (34) .
Overall, our findings suggest that, in routine clinical practice, with a few individual sessions at the start, group treatment is a valid and useful alternative to individual therapy.
Importantly, group treatment may have advantages in terms of cost-effectiveness. In our setting, the total therapist time for one patient treated individually throughout was approximately 12 hours, whereas the therapist time for one patient treated in a group after four individual sessions was 8 hours. Obviously, more detailed costeffectiveness assessments are needed.
Predictors of Outcome
We used psychiatric comorbidity as measured by the SCL-90, pre-treatment motivation (assessed by the stage of change measure, University of Rhode Island, Change Assessment Scale), and completion of the first treatment phase as predictors of outcome. These predictors
were chosen because of their demonstrated importance in previous studies (34, 35) .
Completion of the first treatment phase was the only variable to predict outcome on both patient and therapist assessment, and it only predicted outcome from vomiting. This is noteworthy, as early reduction of vomiting is an important predictor of longer-term treatment success (34) . In the current study, long-term reduction in binge eating was predicted by the initial level of motivation. This supports earlier findings by Treasure et al. (35) in which improvement in binge eating was found for those subjects who shifted into an "active" stage of change. This also suggests that the stage of change may be specific for each of the behaviors (bingeing, vomiting, laxative abuse) and, therefore, should be assessed independently. That different behaviors may respond differently to treatment may advocate for interventions organized around symptoms, rather than diagnoses as suggested by the transdiagnostic model of Fairburn and colleagues (7, 38) .
Limitations
Our study was conducted with minimal resources under routine clinical conditions and, as a result, has a number of methodological limitations. Due to resource constraints, we did not include the "obvious" fourth treatment cell (four sessions CBT followed by eight sessions individual CBT). The inclusion of such a group would have been desirable, as it would have allowed us to assess whether MET enhances outcome relative to CBT, irrespective of whether it is followed by individual or group treatment. We also did not include a notreatment control group. This was neither practical nor given the pragmatic nature of the trial critical to understanding our results, as past studies, including one from our own center, did not show spontaneous improvement in the waiting list condition (39) .
We used patient ratings only for the long-term follow-up in keeping with previous large-scale naturalistic eating disorder outcome studies (27, 28) Previous studies (40) have demonstrated excellent agreement between patient self-assessment tools and expert ratings on self-induced vomiting and on laxative use with lesser agreement on variables, such as bingeing, which require more subjective judgment. This is exactly what we found in the present studypatient/clinician agreement on symptom frequency was better for vomiting and laxative use than for bingeing. However, overall, the inter-rater reliability between patients and therapists for symptoms measured in the present study was high.
It should be noted that, although the assessor at follow-up was blinded, the assessors at post treatment were not blinded to outcome.
We did not include a formal assessment of treatment fidelity or therapist competence through audio-taping of sessions because of resource constraints. However, therapists were regularly supervised, and all interventions used in this study were based on detailed manuals.
Supervisors worked closely with therapists reviewing process notes and the products generated by the individuals or groups.
We only assessed behavioral indicators of change, rather than including dietary restraint or attitudinal aspects of bulimic symptomatology, such as weight and shape. We omitted the latter, as they are more difficult to assess reliably (41) .
A number of our subjects were receiving antidepressant medication. We would not necessarily view this as a limitation, but rather, given the current status of pharmacological treatment of bulimia nervosa, we would view this as a fair reflection of clinic cases.
Importantly, there were no differences between groups in this respect.
We did not include a health economic assessment of patient's total service use during and after treatment and we do not know how many of them received additional treatment for their eating disorder and whether there was any difference in this respect between the groups.
However, given that we are the only NHS treatment center in the area, we can reasonably assume that no other NHS or specialized service was obtained.
Finally, attrition rates were high but in keeping with those in relatively unselected clinic samples (11, 32, 42) . Future studies might want to conduct qualitative interviews to assess the reasons for dropout, but resource constraints prohibited that in the current study. a Coding frequency: "1 = not at all"; "2 = up to 1× week"; "3 = 2 to 3× week"; "4 = 4× week up to daily"; "5 = more 1× day."
*One-way analysis of variance, p value.
MET-I = individual course of motivational enhancement therapy offered before individual cognitive therapy; MET-G = individual motivational enhancement therapy offered before cognitive behavior therapy group; CBT-G = individual cognitive behavior therapy offered before cognitive behavior therapy group; SD = standard deviation; BMI = body mass index. MET-I = individual course of motivational enhancement therapy offered before individual cognitive therapy; MET-G = individual motivational enhancement therapy offered before cognitive behavior therapy group; CBT-G = individual cognitive behavior therapy offered before cognitive behavior therapy group; SD = standard deviation; BMI = body mass index.
There was no significant group by time interaction on any of the behavioural variables. End of treatment % (n)
1-year follow-up % (n)
1.5-year followup % (n) Bingeing Patient 2.5 (38) 29 (32) 40 (22) 46 ( 
